Dr Mick Hunter joined Oxagen in 2001 and has responsibility for the department of drug discovery which includes chemistry and biology functions. Mick was instrumental in the transition of Oxagen from a genetics platform based company into its current drug discovery and development focus.

Mick is project director on Oxagen’s lead CRTH2 antagonist development program which involves management of outsourced functions needed for prosecution of drug programmes up to first time in human studies. He has experience of leading teams to identify IND candidates and managing them through early clinical development. He is familiar with regulatory environments and has managed biological pilot plants for GMP manufacture.

Prior to joining Oxagen Mick held positions at British Biotech Pharmaceuticals (now Vernalis PLC) and before that was at Searle Pharmaceuticals UK and USA.